Chengdu Zenitar Biomedical Technology
Chengdu Zenitar Biomedical Technology is a Chinese developer in Chengdu that sponsors 6 registered cancer trials of Purinostat and Purinostat Mesylate.
Overview
Chengdu Zenitar Biomedical Technology appears on ClinicalTrials.gov as the industry sponsor of 6 interventional cancer trials (phase 1/2, 2, 3), testing Purinostat, Purinostat Mesylate, Selinexor, Flonoltinib in advanced solid tumor, recurrent and refractory diffuse large b-cell lymphoma, diffuse large b cell lymphoma，dlbcl, polycythemia vera (pv). OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.
Similar pages
not linked directly; found by shared links- TreatmentPurinostat
Shares A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors, A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma, A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma, Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
- CompanyBeijing Gene Key Life Technology
Shares the tags china, registry-only.
- CompanyBeijing Konruns Pharmaceutical
Shares the tags china, registry-only.
- CompanyBeijing Mabworks Biotech
Shares the tags china, registry-only.
- CompanyBeijing Pearl Biotechnology Limited Liability Company
Shares the tags china, registry-only.
- CompanyBeijing Scitech-Mq Pharmaceuticals
Shares the tags china, registry-only.
- CompanyBeijing Tide Pharmaceutical
Shares the tags china, registry-only.
- CompanyBinhui Biopharmaceutical
Shares the tags china, registry-only.